https://scholars.lib.ntu.edu.tw/handle/123456789/467955
標題: | Functional role of soluble receptor for advanced glycation end products in stroke | 作者: | SUNG-CHUN TANG Wang Y.-C. Li Y.-I. Lin H.-C. Manzanero S. Hsieh Y.-H. Phipps S. Hu C.-J. Chiou H.-Y. Huang Y.-S. WEI-SHIUNG YANG Mattson M.P. Arumugam T.V. JIANN-SHING JENG |
公開日期: | 2013 | 卷: | 33 | 期: | 3 | 起(迄)頁: | 585-594 | 摘要: | Objective-Little is known about the involvement of the soluble form of receptor for advanced glycation end products (sRAGE) in acute ischemic stroke (IS). Here, we aim to identify the role of plasma sRAGE and high mobility group box 1 (HMGB1) in imaging-confirmed IS patients, as well as mice subjected to focal ischemic stroke. Methods and Results-IS patients were recruited and plasma samples were collected for the measurement of sRAGE and HMGB1 after stroke. The relation of sRAGE and HMGB1 with acute IS was also investigated in a C57BL/6J mouse model of focal ischemic stroke and primary cortical neurons subjected to oxygen and glucose deprivation. Plasma levels of sRAGE and HMGB1 were both significantly increased within 48 hours after IS, and the sRAGE level was an independent predictor of functional outcome at 3 months poststroke. Immunoprecipitation assays revealed that the binding of plasma HMGB1 to sRAGE increased progressively after IS both in patients and mice. Administration of recombinant sRAGE significantly reduced infiltrating immune cells and improved the outcome of injury in mice, protected cultured neurons against oxygen and glucose deprivation-induced cell death, and ameliorated the detrimental effect of recombinant HMGB1. Conclusion-Early poststroke plasma sRAGE may play a protective role in IS by capturing HMGB1. Hence, recombinant sRAGE is a potential therapeutic agent in acute IS. ? 2013 American Heart Association, Inc. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/467955 | ISSN: | 1079-5642 | DOI: | 10.1161/ATVBAHA.112.300523 | SDG/關鍵字: | advanced glycation end product receptor; creatinine; glucose; hemoglobin A1c; high mobility group B1 protein; neuroprotective agent; recombinant protein; recombinant soluble advanced glycation end product receptor; unclassified drug; adult; animal experiment; animal model; article; body mass; brain cell; brain cortex; brain infarction size; brain injury; brain ischemia; brain tissue; cell death; cell infiltration; cell survival; cell viability; cerebrovascular accident; controlled study; diabetes mellitus; diastolic blood pressure; disease severity; embryo; female; functional assessment; heart atrium fibrillation; human; human tissue; hyperlipidemia; hypertension; immunocompetent cell; immunocytochemistry; immunohistochemistry; immunoprecipitation; male; mouse; nonhuman; outcome assessment; priority journal; protein function; reperfusion injury; smoking habit; systolic blood pressure; Adult; Aged; Aged, 80 and over; Analysis of Variance; Animals; Biological Markers; Case-Control Studies; Cell Death; Cell Hypoxia; Cells, Cultured; Cerebral Cortex; Chi-Square Distribution; Disease Models, Animal; Female; Glucose; HMGB1 Protein; Humans; Immunoprecipitation; Infarction, Middle Cerebral Artery; Logistic Models; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Neurons; Neuroprotective Agents; Oxygen; Prognosis; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Immunologic; Risk Factors; Stroke; Taiwan; Time Factors; Up-Regulation |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。